Related Experiment Video
Updated: Nov 6, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
microRNA-454-mediated NEDD4-2/TrkA/cAMP axis in heart failure: Mechanisms and cardioprotective implications
Yaowen Wang1, Wei Pan1, Xinyu Bai2
1Department of Cardiology, Chongqing Cardiac Arrhythmias Therapeutic Service Center, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Abstract:
The current study aimed to investigate the mechanism by which miR-454 influences the progression of heart failure (HF) in relation to the neural precursor cell expressed, developmentally downregulated 4-2 (NEDD4-2)/tropomyosin receptor kinase A (TrkA)/cyclic adenosine 3',5'-monophosphate (cAMP) axis. Sprague-Dawley rats were used to establish a HF animal model via ligation of the left anterior descending branch of the coronary artery. The cardiomyocyte H9c2 cells were treated with H2 O2 to stimulate oxidative stress injury in vitro. RT-qPCR and Western blot assay were subsequently performed to determine the expression patterns of miR-454, NEDD4-2, TrkA, apoptosis-related proteins and cAMP pathway markers. Dual-luciferase reporter gene assay coupled with co-immunoprecipitation was performed to elucidate the relationship between miR-454, NEDD4-2 and TrkA. Gain- or loss-of-function experiments as well as rescue experiments were conducted via transient transfection (in vitro) and adenovirus infection (in vivo) to examine their respective functions on H9c2 cell apoptosis and myocardial damage. Our results suggested that miR-454 was aberrantly downregulated in the context of HF, while evidence was obtained suggesting that it targeted NEDD4-2 to downregulate NEDD4-2 in cardiomyocytes. miR-454 exerted anti-apoptotic and protective effects on cardiomyocytes through inhibition of NEDD4-2, while NEDD4-2 stimulated ubiquitination and degradation of TrkA protein. Furthermore, miR-454 activated the cAMP pathway via the NEDD4-2/TrkA axis, which ultimately suppressed cardiomyocyte apoptosis and attenuated myocardial damage. Taken together, the key findings of the current study highlight the cardioprotective role of miR-454, which is achieved through activation of the cAMP pathway by impairing NEDD4-2-induced TrkA ubiquitination.
Insights
MicroRNA-454 (miR-454) protects against heart failure by inhibiting NEDD4-2, which prevents TrkA degradation and activates the cAMP pathway, reducing cardiomyocyte apoptosis and myocardial damage.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Biochemistry
Background:
- Heart failure (HF) involves complex molecular mechanisms.
- The role of microRNAs in HF pathogenesis is an area of active investigation.
- Understanding specific regulatory axes is crucial for developing therapeutic strategies.
Purpose of the Study:
- To elucidate the mechanism of miR-454 in heart failure progression.
- To investigate the interplay between miR-454, NEDD4-2, TrkA, and the cAMP pathway.
- To determine the therapeutic potential of miR-454 in mitigating cardiac damage.
Main Methods:
- Established a rat model of heart failure and used H2O2-induced oxidative stress in H9c2 cells.
- Utilized RT-qPCR, Western blot, dual-luciferase reporter assays, and co-immunoprecipitation.
- Performed gain/loss-of-function and rescue experiments in vitro and in vivo.
Main Results:
- miR-454 was downregulated in heart failure and targeted NEDD4-2, reducing its expression.
- miR-454 inhibited NEDD4-2-mediated ubiquitination and degradation of TrkA.
- miR-454 activated the cAMP pathway via the NEDD4-2/TrkA axis, suppressing apoptosis and damage.
Conclusions:
- miR-454 exhibits a cardioprotective role in heart failure.
- The mechanism involves inhibiting NEDD4-2 to stabilize TrkA and activate the cAMP pathway.
- Targeting the miR-454/NEDD4-2/TrkA/cAMP axis offers a potential therapeutic strategy for heart failure.
More Related Videos
08:22Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
Published on: September 15, 2018
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cardiomyopathy II: Dilated Cardiomyopathy